Farther Finance Advisors LLC Boosts Stake in Gilead Sciences, Inc. $GILD

Key Points

• Farther Finance Advisors LLC increased its stake in Gilead Sciences, Inc. by 11.3%, acquiring an additional 4,223 shares, bringing their total holdings to 41,710 shares valued at $4,624,000.
• CEO Daniel Patrick O'day sold 10,000 shares of Gilead stock for over $1.13 million, marking a 1.65% decrease in his shareholding.
• Gilead Sciences recently announced a quarterly dividend of $0.79 per share, representing an annualized yield of 2.8%.

Farther Finance Advisors LLC increased its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 11.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 41,710 shares of the biopharmaceutical company's stock after buying an additional 4,223 shares during the quarter. Farther Finance Advisors LLC's holdings in Gilead Sciences were worth $4,624,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. Brighton Jones LLC raised its holdings in shares of Gilead Sciences by 20.6% during the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock valued at $1,326,000 after buying an additional 2,450 shares during the last quarter. Bison Wealth LLC bought a new position in shares of Gilead Sciences during the 4th quarter worth about $215,000. Fourth Dimension Wealth LLC acquired a new position in Gilead Sciences in the fourth quarter valued at about $54,000. Sunbelt Securities Inc. raised its stake in shares of Gilead Sciences by 6.2% during the fourth quarter. Sunbelt Securities Inc. now owns 16,680 shares of the biopharmaceutical company's stock worth $1,535,000 after buying an additional 977 shares during the last quarter. Finally, Twin Lakes Capital Management LLC increased its stake in Gilead Sciences by 0.6% in the fourth quarter. Twin Lakes Capital Management LLC now owns 75,296 shares of the biopharmaceutical company's stock valued at $6,955,000 after purchasing an additional 426 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Gilead Sciences news, CEO Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock in a transaction dated Thursday, August 28th. The stock was sold at an average price of $113.63, for a total transaction of $1,136,300.00. Following the transaction, the chief executive officer owned 595,725 shares of the company's stock, valued at $67,692,231.75. The trade was a 1.65% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the company's stock in a transaction on Monday, September 15th. The shares were sold at an average price of $113.57, for a total value of $283,925.00. Following the completion of the transaction, the chief financial officer owned 159,555 shares of the company's stock, valued at $18,120,661.35. The trade was a 1.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 82,000 shares of company stock worth $9,390,030. Company insiders own 0.27% of the company's stock.

Wall Street Analyst Weigh In

GILD has been the topic of several research reports. Dbs Bank raised Gilead Sciences to a "moderate buy" rating in a research report on Friday, September 5th. UBS Group upped their target price on shares of Gilead Sciences from $108.00 to $112.00 and gave the stock a "neutral" rating in a research note on Friday, August 8th. Royal Bank Of Canada increased their price target on shares of Gilead Sciences from $96.00 to $98.00 and gave the company a "sector perform" rating in a research report on Friday, August 8th. Needham & Company LLC raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price target on the stock in a report on Friday, July 25th. Finally, JPMorgan Chase & Co. raised their target price on shares of Gilead Sciences from $135.00 to $145.00 and gave the stock an "overweight" rating in a report on Tuesday, September 16th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and six have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $117.17.

Gilead Sciences Stock Performance

Shares of GILD opened at $114.09 on Friday. The company has a market capitalization of $141.56 billion, a price-to-earnings ratio of 22.73, a price-to-earnings-growth ratio of 0.77 and a beta of 0.36. Gilead Sciences, Inc. has a 52-week low of $81.83 and a 52-week high of $121.83. The stock has a 50 day moving average price of $114.10 and a 200 day moving average price of $110.03. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm had revenue of $7.08 billion during the quarter, compared to analysts' expectations of $6.95 billion. During the same quarter in the prior year, the business posted $2.01 earnings per share. Gilead Sciences's revenue was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be paid a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date is Monday, September 15th. Gilead Sciences's payout ratio is currently 62.95%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.